T
ech
CN
library_books
Mobile
library_books
Laptop/Pc
library_books
Smart Home
library_books
Audio
library_books
Games
Lastnews
Topics
Trending
News
Best Pick
Reviews
How To Do
Search ...
European Medicines Agency Expedites Assessment of Revolution Medicines’ Daraxonrasib Under Phased Review Process
Notified -...
Curium Announces a Strategic Investment of Over €32 million in Saclay, France
Notified -...
Daraxonrasib Demonstrates Unprecedented Overall Survival Benefit in Pivotal Phase 3 RASolute 302 Clinical Trial in Patients with Metastatic Pancreatic Cancer
Notified -...
Io Therapeutics, Inc. announces publication in Scientific Reports – Nature, of studies showing synergistic efficacy of its RXR agonist IRX4204 with the standard of care drug lenalidomide against multiple myeloma.
Notified -...
Io Therapeutics, Inc. announces publication of studies on the company’s RXR agonist compound IRX4204 for breast cancer prevention
Notified -...
Hummingbird Bioscience Announces First Patient Dosed in Phase I Clinical Trial of HMBD-501 in Advanced HER3-Expressing Solid Malignancies
Notified -...
Bioptimus Assembles Elite Scientific Advisory Board to Build Next-Gen AI Models for Biology
Notified -...
Workplace Options Unveils Comprehensive & Compassionate Return-to-Work Program for Cancer Survivors
Notified -...
Hummingbird Bioscience Licenses Novel Antibodies to Immunome
Notified -...
Io Therapeutics, Inc., announces presentation of data on its RAR gamma agonist compound IRX5010 demonstrating inhibition of tumor infiltrating myeloid derived suppressor cells, promotion of tumor infiltrating T-cells, and effective tumor growth inhibition
...
1
2
menu
TechCN
person
menu
